Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
Key Laboratory of Cancer Immunotherapy of Chongqing, Chongqing, China (mainland).
Ann Transplant. 2021 Oct 12;26:e933365. doi: 10.12659/AOT.933365.
BACKGROUND High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) plays a crucial role in the therapy of patients with lymphoma. This retrospective study aimed to analyze prognostic factors in patients undergoing HDT/ASCT for lymphoma. MATERIAL AND METHODS We included patients with lymphoma who underwent HDT/ASCT at our center. Time-to-event outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed with the Kaplan-Meier method and log-rank test. Receiver operating characteristic (ROC) curve analysis and Cox proportional hazard regression analysis were performed to explore the prognostic value of different factors. RESULTS A total of 113 patients with lymphoma were included. Patients with low serum albumin levels (<37 g/L) before transplantation had significantly lower PFS and OS (P<0.01). Albumin levels before transplantation significantly predicted early progression (progressed within 1 year) after transplantation (AUC=0.706, P=0.003). Multivariate Cox analysis indicated that low albumin level (hazard ratio [HR] 3.19, 95% confidence interval [CI] 1.54-6.63; P=0.002) and age >60 years (HR 2.92, 95% CI 1.27-6.71; P=0.012) were independent risk factors for PFS. Total protein <60 g/L was an independent risk factor for OS (HR 3.57, 95% CI 1.45-8.78; P=0.006). CONCLUSIONS Low albumin level before transplantation was an independent risk factor in patients with lymphoma undergoing HDT/ASCT. Intense care and effective maintenance therapy after transplantation are required for patients with low albumin levels.
大剂量化疗联合自体造血干细胞移植(HDT/ASCT)在淋巴瘤患者的治疗中起着至关重要的作用。本回顾性研究旨在分析接受 HDT/ASCT 的淋巴瘤患者的预后因素。
我们纳入了在我院接受 HDT/ASCT 的淋巴瘤患者。采用 Kaplan-Meier 法和对数秩检验分析无进展生存(PFS)和总生存(OS)等时间事件结局。采用接收者操作特征(ROC)曲线分析和 Cox 比例风险回归分析探讨不同因素的预后价值。
共纳入 113 例淋巴瘤患者。移植前血清白蛋白水平<37 g/L 的患者 PFS 和 OS 明显降低(P<0.01)。移植前白蛋白水平显著预测移植后早期进展(1 年内进展)(AUC=0.706,P=0.003)。多因素 Cox 分析表明,低白蛋白水平(危险比[HR]3.19,95%置信区间[CI]1.54-6.63;P=0.002)和年龄>60 岁(HR 2.92,95%CI 1.27-6.71;P=0.012)是 PFS 的独立危险因素。总蛋白<60 g/L 是 OS 的独立危险因素(HR 3.57,95%CI 1.45-8.78;P=0.006)。
移植前低白蛋白水平是接受 HDT/ASCT 的淋巴瘤患者的独立危险因素。对于低白蛋白水平的患者,移植后需要进行强化护理和有效的维持治疗。